Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
0.577 USD | -2.48% | +1.47% | +5.41% |
Financials (USD)
Sales 2024 * | 38.83M | Sales 2025 * | 70.15M | Capitalization | 123M |
---|---|---|---|---|---|
Net income 2024 * | -107M | Net income 2025 * | -46M | EV / Sales 2024 * | 4.21 x |
Net Debt 2024 * | 40.79M | Net Debt 2025 * | 129M | EV / Sales 2025 * | 3.59 x |
P/E ratio 2024 * |
-1.23
x | P/E ratio 2025 * |
-2.67
x | Employees | 405 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.89% |
Latest transcript on Sangamo Therapeutics, Inc.
1 day | +1.08% | ||
1 week | +8.53% | ||
Current month | +4.84% | ||
1 month | +12.38% | ||
3 months | -41.42% | ||
6 months | +32.05% | ||
Current year | +8.91% |
Managers | Title | Age | Since |
---|---|---|---|
Alexander Macrae
CEO | Chief Executive Officer | 61 | 16-05-31 |
Director of Finance/CFO | 45 | 19-02-28 | |
Gregory Davis
CTO | Chief Tech/Sci/R&D Officer | - | 20-04-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Peg Horn
BRD | Director/Board Member | 61 | 22-12-14 |
James Meyers
BRD | Director/Board Member | 59 | 19-11-21 |
H. Parker
CHM | Chairman | 68 | 14-06-18 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
3.66% | 2 M€ | -25.75% | ||
0.49% | 14 M€ | -3.61% |
Date | Price | Change | Volume |
---|---|---|---|
24-06-07 | 0.5727 | -3.21% | 932 311 |
24-06-06 | 0.5917 | +1.08% | 1,194,219 |
24-06-05 | 0.5854 | +3.14% | 1,272,633 |
24-06-04 | 0.5676 | -2.61% | 1,560,916 |
24-06-03 | 0.5828 | +3.26% | 1,306,394 |
Delayed Quote Nasdaq, June 06, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+8.91% | 123M | |
+19.33% | 125B | |
+13.95% | 108B | |
-3.53% | 24.57B | |
+4.54% | 22.82B | |
-10.32% | 18.19B | |
-41.48% | 16.54B | |
-12.62% | 16.5B | |
+0.99% | 13.39B | |
+21.79% | 11.1B |
- Stock Market
- Equities
- SGMO Stock